Netarsudil Ophthalmic Solution 0.02%: First Global Approval

Netarsudil ophthalmic solution 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa ® ] is a Rho-associated protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aqueous humour outflow through the trabecular meshwork. It has been developed by Aerie Pharma...

Full description

Saved in:
Bibliographic Details
Published in:Drugs (New York, N.Y.) N.Y.), 2018-03, Vol.78 (3), p.389-396
Main Author: Hoy, Sheridan M.
Format: Article
Language:English
Subjects:
AdisInsight Report
Agreements
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - adverse effects
Antihypertensive Agents - pharmacology
Antihypertensive Agents - therapeutic use
Aqueous humour
Asset acquisitions
Benzoates - administration & dosage
Benzoates - adverse effects
Benzoates - pharmacology
Benzoates - therapeutic use
beta-Alanine - administration & dosage
beta-Alanine - adverse effects
beta-Alanine - analogs & derivatives
beta-Alanine - pharmacology
beta-Alanine - therapeutic use
Clinical Trials as Topic
Collaboration
Drug Approval
Drug dosages
Enzyme inhibitors
Extracellular matrix
FDA approval
Glaucoma
Glaucoma, Open-Angle - drug therapy
Humans
Hypertension
Internal Medicine
Intraocular pressure
Intraocular Pressure - drug effects
Kinases
Medicine
Medicine & Public Health
Ophthalmic Solutions
Patients
Pharmaceuticals
Pharmacology/Toxicology
Pharmacotherapy
Protein kinase inhibitors
Proteins
Reduction
rho-Associated Kinases - antagonists & inhibitors
Trabecular Meshwork - drug effects
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Netarsudil ophthalmic solution 0.02% (hereafter referred to as netarsudil 0.02%) [Rhopressa ® ] is a Rho-associated protein kinase inhibitor that is thought to lower intraocular pressure (IOP) by increasing aqueous humour outflow through the trabecular meshwork. It has been developed by Aerie Pharmaceuticals and was recently approved in the USA for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. The recommended dosage is one drop in the affected eye(s) once daily in the evening. Phase III development in the EU and phase II development in Japan are underway for this indication. This article summarizes the milestones in the development of netarsudil 0.02% leading to this first approval for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-018-0877-7